APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-28

Price

$134.97

+0.01%

This is the 2026-08-28 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score11.0Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

Apogee Therapeutics is exhibiting classic merger arbitrage price action following recent shareholder approval of its $135.11 per share cash acquisition by AbbVie. The technical signals, including QUIET_STORM and PERFECT_STACK, alongside an ultra-low 1.4% annualized volatility, perfectly reflect the stock pinning just below the final deal price. The current RISK_ON macro regime, characterized by exceptionally tight credit spreads (0.79%) and a low VIX, provides immense market confidence that the $10.9 billion transaction will close without financing or regulatory hurdles.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: APGE is a pure merger arbitrage play, trading mere cents below the definitive $135.11 AbbVie cash acquisition price.
Key Risk: Regulatory intervention or unexpected termination of the AbbVie deal, which would cause a severe repricing.
What to Watch: Final regulatory clearances and the official deal closing expected in Q3 2026.

← Back to 2026-08-28 View Full APGE History →Yahoo Finance &nearr;